Domains targeting keyword anemia treatment
Keyword anemia treatment was used in the provided list of websites.
Number of websites/domains displayed: 13
Results found: 13
Similar searches:
Websites discovered:
Iron Deficiency Anemia Treatment | INJECTAFER®http://pageoverview.com/website-report/injectafer.com
Learn about INJECTAFER® (ferric carboxymaltose injection), a treatment option for iron deficiency anemia. See Full Prescribing & Safety Info.
- Expected expiration: November 3rd in 2018
- Creation date: November 3rd in 2005
- Renew date: November 4th in 2017
Homehttp://pageoverview.com/website-report/feraheme.com
Feraheme (ferumoxytol) Injection for intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease
- Expected expiration: November 26th in 2018
- Creation date: November 26th in 2007
- Renew date: April 10th in 2012
Ontario Hyperbaric Oxygen Therapy Centre | Ontario HBOThttp://pageoverview.com/website-report/ontariohbot.ca
Ontario's Premier Hyperbaric Facility located in Toronto, Canada. OHIP and Private billing available. Concussion, Non-Healing Wounds and Chronic Anemia.
- Expected expiration: August 4th in 2018
- Creation date: August 4th in 2009
- Renew date: August 3rd in 2017
- Google Analytics: 63800316-2
Képeslaphttp://pageoverview.com/website-report/levelezolap.hu
- Creation date: February 15th in 2012
- Google Analytics: 30486334-1
- Adsense ID: pub-1287866530960136
Épületgépészeti webáruházhttp://pageoverview.com/website-report/epuletgepeszaruhaz.hu
Épületgépész webáruház
- Creation date: May 9th in 2008
- Google Analytics: 5543543-2
Inducing Remission in GPA & MPA Patients | Rituxan® GPA & MPA | HCPhttp://pageoverview.com/website-report/rituxanforgpampa-hcp.com
Find information for healthcare professionals about Rituxan® (rituximab), the only FDA-approved treatment proven to induce remission in patients with GPA and MPA. INDICATION STATEMENT - Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Limitations of Use: Rituxan is not recommended for use in patients with severe, active infections BOXED WARNINGS and Additional Important Safety Information BOXED WARNINGS Infusion Reactions: Rituxan administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML): PML, including fatal PML, can occur in patients receiving Rituxan. Warnings and Precautions Rituxan administration can also result in additional serious, including fatal, adverse reactions including: - Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti‑hyperuricemic agents, monitor renal function - Infections: Withhold Rituxan and institute appropriate anti-infective therapy - Cardiac arrhythmias and angina: Discontinue infusions in case of serious or life-threatening events - Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms - Live virus vaccines: Do not administer live virus vaccines prior to or during Rituxan - Cytopenias: Monitor blood counts at regular intervals Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with Rituxan. Observe patients with GPA and MPA closely for signs of infection if immunosuppressants other than corticosteroids are used concomitantly - The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA - Common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see the Rituxan full prescribing information, including BOXED WARNINGS.
- Expected expiration: November 27th in 2019
- Creation date: November 27th in 2013
- Renew date: December 1st in 2017
- Google Analytics: 48974804-1
Right Diagnosishttp://pageoverview.com/website-report/rightdiagnosis.com
Extensive knowledge base of medical information on symptoms, diagnosis, and misdiagnosis of more than 20,000 medical conditions. Research causes of your symptoms or research treatments for diseases.
- Expected expiration: September 14th in 2019
- Creation date: September 14th in 2005
- Renew date: July 18th in 2016
- Google Analytics: 387705-1
- Adsense ID: pub-299288356258400
Hemolytic Anemia: Types, Causes, Symptoms, and Treatmenthttp://pageoverview.com/website-report/hemolyticanemia.org
Hemolytic anemia occurs when red blood cell dies before their normal lifespan of 120 days. It can be inherited or acquired.
- Expected expiration: November 25th in 2017
- Creation date: November 25th in 2015
- Renew date: November 25th in 2016
- Google Plus Account: +HemolyticanemiaOrg
Nutrition, Diet Program, Health, Fitness, Weight Loss, Weight Gain, Metabolism, Healthy Body, Holistic Treatment, Fatigue Treatment, Herbal Treatment, Body Tune Up Nutrition Therapy Centerhttp://pageoverview.com/website-report/btuneup.com
Tune up your bods, End up your odds
- Expected expiration: October 8th in 2017
- Creation date: October 8th in 2011
- Renew date: August 27th in 2016
Pernicious Anaemia Society | Supporting people with pernicious anaemia world-widehttp://pageoverview.com/website-report/pernicious-anaemia-society.org
What is Pernicious Anaemia? What are the Symptoms? B12 deficiency and Pernicious Anaemia, what is the difference? Find out more and get help and support
- Expected expiration: January 28th in 2018
- Creation date: January 28th in 2006
- Renew date: March 14th in 2017
- Google Analytics: 91835778-1
- Google Plus Account: 100368175159368111437
Venofer® (iron sucrose injection, USP)http://pageoverview.com/website-report/venofer.com
Venofer® (iron sucrose injection, USP) provides first-line IV iron therapy for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 2 years and older with chronic kidney disease (CKD).
- Expected expiration: April 24th in 2018
- Creation date: April 24th in 2002
- Renew date: March 30th in 2016
- Google Analytics: 10494479-8
Iron Deficiency Anemia Treatment | INJECTAFER® HCPhttp://pageoverview.com/website-report/injectaferhcp.com
Learn about INJECTAFER® (ferric carboxymaltose injection) for patients with iron deficiency anemia. See Full Prescribing & Safety Info.
- Expected expiration: May 31st in 2020
- Creation date: May 31st in 2017
- Renew date: May 31st in 2017